8 research outputs found

    Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years.

    Get PDF
    (1) Background: We investigated the incidence and survival trends for pancreatic cancer (PC) over the last 25 years in the Girona region, Catalonia, Spain; (2) Methods: Data were extracted from the population-based Girona Cancer Registry. Incident PC cases during 1994-2015 were classified using the International Classification of Diseases for Oncology Third Edition (ICD-O-3). Incidence rates age-adjusted to the European standard population (ASRE) and world standard population (ASRW) were obtained. Trends were assessed using the estimated annual percentage of change (EAPC) of the ASRE13. Observed and relative survivals (RS) were estimated with the Kaplan-Meier and Pohar Perme methods, respectively; (3) Results: We identified 1602 PC incident cases. According to histology, 44.4% of cases were exocrine PC, 4.1% neuroendocrine, and 51.1% malignant-non-specified. The crude incidence rate (CR) for PC was 11.43 cases-per-100,000 inhabitants/year. A significant increase of incidence with age and over the study period was observed. PC overall 5-year RS was 7.05% (95% confidence interval (CI) 5.63; 8.84). Longer overall survival was observed in patients with neuroendocrine tumours (5-year RS 61.45%; 95% CI 47.47; 79.55). Trends in 5-year RS for the whole cohort rose from 3.27% (95% CI 1.69-6.35) in 1994-1998 to 13.1% (95% CI 9.98; 17.2) in 2010-2015; (4) Conclusions: Incidence rates of PC in Girona have increased in the last two decades. There is a moderate but encouraging increase in survival thorough the study period. These results can be used as baseline for future research.S

    Exploring the Associations of Inflammatory and Oxidative Stress Biomarkers with Pancreatic Diseases: An Observational and Mendelian Randomisation Study

    Full text link
    Identifying biomarkers linked to pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP) is crucial for early detection, treatment, and prevention. Methods: Association analyses of 10 serological biomarkers involved in cell signalling (IFN-gamma, IL-6, IL-8, IL-10), oxidative stress (superoxide dismutase (SOD) and glutathione peroxidase (GPx) enzyme activities, total glutathione (GSH), malondialdehyde (MDA) levels), and intestinal permeability proteins (zonulin, I-FABP2) were conducted across PDAC (n = 12), CP (n = 21) and control subjects (n = 23). A Mendelian randomisation (MR) approach was used to assess causality of the identified significant associations in two large genetic cohorts (FinnGen and UK Biobank). Results: Observational results showed a downregulation of SOD and GPx antioxidant enzyme activities in PDAC and CP patients, respectively, and higher MDA levels in CP patients. Logistic regression models revealed significant associations between CP and SOD activity (OR = 0.21, 95% CI [0.05, 0.89], per SD), GPx activity (OR = 0.28, 95% CI [0.10, 0.79], per SD), and MDA levels (OR = 2.05, 95% CI [1.36, 3.08], per SD). MR analyses, however, did not support causality. Conclusions: These findings would not support oxidative stress-related biomarkers as potential targets for pancreatic diseases prevention. Yet, further research is encouraged to assess their viability as non-invasive tools for early diagnosis, particularly in pre-diagnostic CP populations

    Valor pronóstico del estudio molecular en tumores de células germinales y su relación con la resistencia al cisplatino

    Get PDF
    El propósito de este estudio es la caracterización molecular de una cohorte de pacientes diagnosticados de TCG en estadío avanzado y tratados en diferentes centros españoles, con el fin de establecer un perfil que defina la respuesta al tratamiento quimioterápico y una posible resistencia al cisplatino. Se trata de describir el patrón de expresión de las proteínas implicadas en el ciclo celular p53, mdm2, ciclina D1 y ciclina D2, analizadas por inmunohistoquímica, en las biopsias de tumores de células germinales de pacientes diagnosticados en distintos hospitales de nuestro país y tratados en el Hospital 12 de Octubre en el periodo tiempo incluido entre 1977-2003. Y por otro lado, determinar la posible relación de cada uno de los marcadores moleculares estudiados con: la respuesta al tratamiento basado en cisplatino, la supervivencia libre de enfermedad y la supervivencia global de los pacientes

    Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia

    No full text
    Este artículo ha sido publicado en la revista Cancer Esta versión tiene Licencia Creative Commons CC-BY-NC-ND Aportamos pdf que hemos recibido de la revista ante nuestra solicitud de postprint, con permiso de la revista "Thank you for reaching out. The article can be accessed and downloaded here: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.20275Cancer patients with fever and neutropenia currently are assessed on clinical grounds only. The current study prospectively evaluated the efficacy of baseline procalcitonin (PCT) in the detection of bacteremia and in the prediction of outcome in patients with solid tumors and febrile neutropenia. METHODS. PCT levels were determined at baseline and every 48 hours in 104 patients undergoing chemotherapy who developed fever (axillary temperature 38 °C on 2 occasions or 38.3 °C in a single record) and neutropenia (absolute neutrophil count 500 cells/ L). RESULTS. The median baseline PCT values were significantly higher in patients who had microbiologically documented infections (1.24 ng/mL) compared with patients who had clinically documented infections (0.27 ng/mL) or fever of unknown origin (0.21 ng/mL; P 0.01). Accordingly, a PCT cut-off value of 0.5 ng/mL was reached more frequently in patients who had microbiologically documented infections compared with patients who had clinically documented infections or fever of unknown origin (66.7% vs. 13.4%, respectively; P 0.001). Furthermore, this threshold also was associated with an increased likelihood of treatment failure (70.0% vs. 14.9%; P 0.001). All 4 septic patients and all 5 patients who ultimately died presented PCT values 5-fold to 10-fold greater than the median values. Clinical evaluation in combination with baseline PCT assessment appeared to improve clinical risk evaluation alone. CONCLUSIONS. Baseline PCT levels were higher in patients who had febrile neutropenia with bacteremia compared with patients who had clinical infections or fever of unknown origin. PCT helped to identify patients who had microbiologic infections and patients who were at high risk of treatment failure, and PCT may constitute a complementary tool in the initial assessment of such pati

    Diseño del título de Grado en Información y Documentación

    Get PDF
    This paper describes the methodology followed by the Professor of Library and Information Science Department of the Documentation and History of Science for the planning and design at the University of Zaragoza's graduate degree in Information and Documentation in accordance with the requirements in RD 1393/2007, of 29 October, by establishing the management of official university studie

    SIDA

    No full text
    En la cub. : Diputación Provincial de Córdoba, Centro Provincial de Drogodependencias. Contiene : SIDA : tratamiento educativo en educación primaria, SIDA : tratamiento educativo en educación secundariaMaterial que proporciona algunos puntos de partida para considerar la temática en torno al SIDA dentro de las propuestas curriculares del centro y del aula. Hay talleres y cuadernillos de investigación para el alumnado de tercer ciclo de primaria , ESO y bachillerato. Ofrece pautas metodológicas y consideraciones generales sobre la propuesta. Material sencillo y útil de manejar por el profesorado y asequible para el alumnado.AndalucíaBiblioteca de Educación del Ministerio de Educación, Cultura y Deporte; Calle San Agustín, 5; 28014 Madrid; Tel. +34917748000; [email protected]

    Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey

    No full text
    corecore